Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

Post by overnouton Mar 09, 2022 4:41pm
205 Views
Post# 34500924

Return to Glory Days

Return to Glory Days

MISSISSAUGA, OntarioMarch 09, 2022 (GLOBE NEWSWIRE) --  BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2021. Key highlights include:  

  • Fourth quarter (Q4) 2021 Net Revenues of $7,218,656 increased by 26% versus Q4 2020
  • Full year (FY) 2021 Net Revenues of $28,618,218 increased by 28% versus FY 2020
  • Q4 2021 Canadian Pharmaceutical Net Revenues of $6,466,381 increased by 20% versus Q4 2020
  • FY 2021 Canadian Pharmaceutical Net Revenues of $25,780,275 increased by 21% versus FY 2020
  • Q4 2021 International Pharmaceutical Net Revenues of $318,406 increased by 462% versus Q4 2020
  • FY 2021 International Pharmaceutical Net Revenues of $1,623,723 increased by 621% versus FY 2020
  • Q4 2021 EBITDA1 of $2,639,145 increased by 136% versus Q4 2020
  • FY 2021 EBITDA1 of $8,783,726 increased by 57% versus FY 2020
  • Q4 2021 Net Income After Taxes (NIAT) of $1,877,804 increased by 182% versus Q4 2020
  • FY 2021 NIAT of $6,281,566 increased by 66% versus FY 2020
  • Q4 2021 NIAT percentage to Net Revenues of 26% compares to 12% in Q4 2020
  • FY 2021 NIAT percentage to Net Revenues of 22% compares to 17% in FY 2020
  • Q4 2021 Fully Diluted EPS of $0.15 was $0.10 higher than Q4 2020 Fully Diluted EPS of $0.05
  • FY 2021 Fully Diluted EPS of $0.49 was $0.20 higher than FY 2020 Fully Diluted EPS of $0.29
  • As at December 31, 2021, the Company had cash, cash equivalents, and short-term investments totalling $28,211,670 as compared to $25,577,706 as at December 31, 2020 – a 10% increase
  • Total Shareholders’ Equity increased by 18% to $31,554,926 at December 31, 2021 from $26,795,956 at December 31, 2020
  • Return on Equity for the year ended December 31, 2021 was 21% as compared to 14% for the year ended December 31, 2020
  • During FY 2021, repurchased a total of 180,950 common shares under a Normal Course Issuer Bid (NCIB) and a further 124,300 common shares repurchased to date in 2022
<< Previous
Bullboard Posts
Next >>